New C-Code Issued for Onivyde Injection

• Amanda Bridges
• April 25, 2016
• Drugs

Merrimack Pharmaceuticals has announced that the Centers for Medicare & Medicaid Services (CMS) issued a C-code forOnivyde™ (irinotecan liposome injection), effective April 1, 2016: C9474, Injection, irinotecan liposome, 1 mg.

Onivyde (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Learn more here.